The Netherlands Enterprise Agency granted an Innovation Credit (’Innovatiekrediet’) of € 3.4 million to Dutch biopharma SME Alloksys Life Sciences for the execution of phase 3 clinical trials. The goal is to reach registration of RESCAP® (RESCuing Alkaline Phosphatase).

Founded in 2006, Alloksys Life Sciences is developing the platform as an anti-ischemic injury and anti-inflammatory compound in acute clinical settings like open heart and other major surgery, organ transplantation, blood loss trauma and severe burn wounds.



Please enter your comment!
Please enter your name here